ATFirst™ · General health rapid tests
ATFirst™ AFP Rapid Test
A qualitative lateral flow cassette for alpha-fetoprotein (AFP) in whole blood, serum or plasma.
- Professional use
- Whole blood, serum or plasma
- 20 tests per kit
Intended use
Healthcare professionals use the ATFirst™ AFP rapid test to check, qualitatively, whether alpha-fetoprotein in whole blood, serum or plasma is above the level defined in the insert. The result supports clinical assessment and is always read with imaging, history and laboratory findings.
AFP is made by the fetal liver and yolk sac. Its level falls after birth and stays very low in healthy adults, with one normal exception: it rises in the mother’s blood during pregnancy. Outside pregnancy, raised AFP in adults is associated with hepatocellular carcinoma and certain germ cell tumors, and it also occurs in chronic hepatitis and cirrhosis. First Diagnostic™ Corporation distributes the cassette in its ATFirst™ rapid tests range.
Specifications
| Brand | ATFirst™ |
|---|---|
| Catalog number | 85226400135 |
| Format | Lateral flow cassette |
| Analyte / target | Alpha-fetoprotein (AFP) |
| Specimen | Whole blood, serum or plasma |
| Pack size | 20 tests — confirm at quotation |
| Intended user | Healthcare professionals |
| Regulatory | Documentation available on request |
| Instructions for use | Supplied with each kit; current insert on request |
How the test works
The assay is a two-antibody sandwich. AFP in the specimen first meets a labeled anti-AFP antibody, and the pair is then caught by a second anti-AFP antibody printed across the membrane, in the manner usual for antigen cassettes. The control line shows that enough specimen has passed. Reading instructions are in the insert; the principle is covered in lateral flow tests.
What to confirm in the insert
The insert supplied with each kit is the reference for the stated intended use, the AFP detection level, handling of whole blood, serum and plasma, sample volume, read window, storage and interpretation. Check the intended-use statement closely: this page describes no use in prenatal assessment.
We send the current insert on request (sales@firstdiagnostic.com). Published inserts are on the product inserts page.
Limitations
- The test does not diagnose or rule out liver cancer or any other tumor, and is not a population screening tool.
- Pregnancy raises AFP. A reactive result in a pregnant patient cannot be interpreted as a tumor-marker finding.
- Chronic hepatitis and cirrhosis can raise AFP without a tumor, and some liver tumors produce little or none.
- No value is reported; follow-up needs quantitative laboratory AFP.
Frequently asked questions
Is the cassette intended for prenatal testing?
This page makes no such claim. The intended use is the one printed in the insert.
Which specimens are listed?
Whole blood, serum or plasma, in kits of 20 tests under catalog number 85226400135. Pack size is confirmed at quotation.
Do you supply hepatitis tests as well?
Yes. See the ATFirst™ HBsAg rapid test. Distributors can apply through the distributor application.
Related rapid tests
- General health rapid tests — Category overview.
- ATFirst™ CEA rapid test — Carcinoembryonic antigen in serum.
- ATFirst™ PSA rapid test — Prostate-specific antigen.
- What are cancer biomarkers? — Background article.
Ask about the AFP rapid test
Request a quotation and the current insert, or apply for distribution in your territory.
Regulatory status: Products shown on this website are for professional in vitro diagnostic use. They are not cleared, approved or authorized by the U.S. Food and Drug Administration and are not offered for sale in the United States. Product availability and regulatory status vary by country; contact us for the status in your market.